<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00143039</url>
  </required_header>
  <id_info>
    <org_study_id>OBX 0005.3</org_study_id>
    <secondary_id>Tandem MS - 0005.3</secondary_id>
    <nct_id>NCT00143039</nct_id>
  </id_info>
  <brief_title>Amniotic Fluid Tandem Mass Spectrometry for Pregnancies Complicated by NIH and Severe Symmetrical IUGR</brief_title>
  <acronym>TandemMS</acronym>
  <official_title>Amniotic Fluid Tandem Mass Spectrometry for Pregnancies Complicated by Nonimmune Hydrops and Severe Symmetrical Intrauterine Growth Restriction-A Multicenter Prospective Pilot Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Obstetrix Medical Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mednax Center for Research, Education, Quality and Safety</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this pilot study is to prospectively evaluate amniotic fluid of pregnancies&#xD;
      complicated by non-immune hydrops and severe symmetrical intrauterine growth restriction by&#xD;
      tandem mass spectrometry for inborn errors of metabolism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nonimmune hydrops (NIH) and severe symmetrical intrauterine growth restriction (IUGR)&#xD;
      represent two obstetrical circumstances that occur with relative frequency yet often escape&#xD;
      adequate etiology assessment and diagnosis prior to and after birth. Both of these conditions&#xD;
      have high perinatal and neonatal mortality rates. While antepartum ultrasound and amniotic&#xD;
      fluid evaluations of fetal karyotype and viral DNA studies diagnose some etiologies for NIH&#xD;
      and severe symmetrical IUGR, large percentages of NIH (30-40%) and IUGR (20-30%) cases are&#xD;
      attributed to idiopathic causes. Because of this uncertainty in diagnosis, many cases are&#xD;
      subjected to prolonged antepartum hospitalization with intensive fetal monitoring and urgent&#xD;
      delivery by Cesarean section for non-reassuring fetal status, only to succumb to a neonatal&#xD;
      demise in the nursery. A small percentage (1-2%) of these cases are found to be due to inborn&#xD;
      errors of metabolism by neonatal and/or postmortem evaluation; however, when combined&#xD;
      together, greater than 50% of NIH and IUGR cases have no identifiable etiology. Therefore,&#xD;
      any new test that may make a diagnosis for NIH or severe symmetrical IUGR prior to delivery&#xD;
      would be extremely important to the management of both the mother and the infant. Tandem mass&#xD;
      spectrometry for inborn errors of metabolism may represent a new tool for assessing,&#xD;
      identifying, and treating currently unexplained cases of NIH and severe symmetrical IUGR.&#xD;
&#xD;
      This is a prospective pilot cohort study of all pregnancies complicated by NIH and severe&#xD;
      symmetrical IUGR within the Pediatrix-Obstetrix network. This network encompasses several&#xD;
      perinatal sites throughout the United States with corresponding neonatal intensive care units&#xD;
      utilizing a computerized patient database (RDS). The objective of this study is to&#xD;
      prospectively evaluate amniotic fluid of pregnancies complicated by NIH and severe&#xD;
      symmetrical IUGR by a method called tandem mass spectrometry for inborn errors of metabolism.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No metabolic disordered ID'd by TMS in either control/test group at &gt;50%enrolled&#xD;
  </why_stopped>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Will assess whether amniotic fluid tandem mass spectrometry results are valid when compared to neonatal blood samples for normal pregnancies and those pregnancies complicated by NIH and severe symmetrical IUGR.</measure>
    <time_frame>comparrison down with in 2 days of life.</time_frame>
    <description>Will assess whether amniotic fluid tandem mass spectrometry results are valid when compared to neonatal blood samples for normal pregnancies and those pregnancies complicated by NIH and severe symmetrical IUGR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Neonatal Complications</measure>
    <time_frame>during the neonatal period</time_frame>
    <description>Will include neonatal complications in pregnancies complicated by NIH and severe symmetrical IUGR.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">48</enrollment>
  <condition>Hydrops Fetalis</condition>
  <condition>Fetal Growth Retardation</condition>
  <arm_group>
    <arm_group_label>NIH/SSIUGR fetuses</arm_group_label>
    <description>Group 1 includes pregnancies complicated by a fetus with either Non-Immune Hydrops or Severe Symmetrical IUGR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control-Normal fetus</arm_group_label>
    <description>Group 2 includes all normally appearing fetuses on U/S who will be having a diagnostic amniocentesis as part of their routine care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tandem MS test for inborn errors of metabolism</intervention_name>
    <description>Tandem MS spectrometry test will be done on all maternal blood, amniotic fluid and newborn blood samples for both groups.</description>
    <arm_group_label>Control-Normal fetus</arm_group_label>
    <arm_group_label>NIH/SSIUGR fetuses</arm_group_label>
    <other_name>Tandem MS</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnancies complicated by NIH or SSIUGR fetuses as compared to a control group of&#xD;
        pregnancies with normally appearing fetuses requiring a diagnostic amniocentesis as part of&#xD;
        her care.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        NIH Inclusion Criteria:&#xD;
&#xD;
          -  Singleton gestation&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Excess extracellular fluid in at least two fetal sites as noted by ultrasound: abdomen&#xD;
             (ascites), the chest (pleural and pericardial effusions), the skin (edema &gt; 5mm), the&#xD;
             amniotic cavity (polyhydramnios), and the placenta (thickening &gt; 6cm)&#xD;
&#xD;
          -  NIH diagnosis &gt; 15w0d gestation&#xD;
&#xD;
          -  Diagnostic amniocentesis performed at &gt; 15w0d gestation&#xD;
&#xD;
        NIH Exclusion Criteria:&#xD;
&#xD;
          -  Immune-mediated hydrops fetalis as diagnosed by maternal red cell antigens and fetal&#xD;
             anemia suspected by middle cerebral artery doppler ultrasound and/or confirmed by&#xD;
             percutaneous umbilical blood sampling&#xD;
&#xD;
          -  Structural anomaly identified by ultrasound&#xD;
&#xD;
          -  Chromosomal aneuploidy&#xD;
&#xD;
          -  Multiple gestations&#xD;
&#xD;
        IUGR Inclusion Criteria:&#xD;
&#xD;
          -  Singleton gestation&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Severe symmetrical IUGR defined as a &gt; 3 week lag of all fetal ultrasound measurements&#xD;
             (biparietal diameter, head circumference, abdominal circumference, and femur length)&#xD;
&#xD;
          -  IUGR diagnosis between 24-32 weeks gestation&#xD;
&#xD;
          -  Diagnostic amniocentesis performed prior to 32 weeks gestation&#xD;
&#xD;
        IUGR Exclusion Criteria:&#xD;
&#xD;
          -  Asymmetrical IUGR&#xD;
&#xD;
          -  Structural anomaly identified by ultrasound&#xD;
&#xD;
          -  Chromosomal aneuploidy&#xD;
&#xD;
          -  Multiple gestations&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karrie Francois, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatrix-Obstetrix Medical Group, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner Good Sammaritan Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner Desert Samaritan Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saddleback Memorial Medical Center</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Beach Memorial Medical Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90801-1428</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian/St Luke's Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DeKalb Medical Center</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Regional Medical Center</name>
      <address>
        <city>Riverdale</city>
        <state>Georgia</state>
        <zip>30274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harris Methodist Fort Worth Hospital</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122-4307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>August 31, 2005</study_first_submitted>
  <study_first_submitted_qc>September 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2005</study_first_posted>
  <last_update_submitted>December 17, 2014</last_update_submitted>
  <last_update_submitted_qc>December 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NIH</keyword>
  <keyword>Severe Symmetrical IUGR</keyword>
  <keyword>Tandem Mass Spectrometry</keyword>
  <keyword>Nonimmune Hydrops</keyword>
  <keyword>Severe Symmetrical Intrauterine Growth Restriction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Growth Retardation</mesh_term>
    <mesh_term>Hydrops Fetalis</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

